No Data
No Data
No Data
Meinong Biology (301156.SZ): Specializing in R&D, production and sales of feed additives and enzymolysis protein feed ingredients
Gelonghui, May 21丨Meinong Biotech (301156.SZ) said on the investor interactive platform that the company specializes in R&D, production and sales of feed additives and enzymolysis protein feed ingredients. The company always adheres to the business philosophy of “technology drives value, innovation drives development”, implements the customer value proposition of “product leadership, value service, partner growth”, and implements a “centralized differentiation” development strategy. At the product level, adhere to the product strategy of “classification and full nutrition”; at the market level, adhere to the market strategy of “deeply cultivating the domestic market and expanding overseas markets”, and continuously enhance the company's core competition with multiple strategies
Meinong Biotech (301156.SZ): It has now established a sales network in Brazil and other countries and regions
Gelonghui, May 14, 丨 Meinong Biotech (301156.SZ) recently said during a survey reception from institutional investors that the company has always been committed to exploring and developing the international market, and has laid a good foundation for the international market for more than 20 years. At present, the company has established sales networks in various countries and regions such as Vietnam, Russia, Thailand, Myanmar, the Philippines, Japan, South Korea, Pakistan, Bangladesh, Egypt, Jordan, Turkey, and Brazil. The company's future development plan for overseas business: (1) Following the country's “Belt and Road” policy, the company will focus on developing the Southeast Asian market, South Asia and the Middle East market. (2) At
Meinong Biotech (301156.SZ) plans to transfer 10 shares to 3 shares and distribute 5.5 yuan, excluding interest on May 13
Zhitong Finance App News, Meinong Biotech (301156.SZ) announced that the company's 2023 equity distribution plan: 5.5 yuan (tax included) for every 10 shares to all shareholders; at the same time, 3 shares will be transferred to all shareholders for every 10 shares. The ex-dividend date is May 13, 2024.
Meinong Biotech (301156.SZ): Net profit of 9.58 million yuan in the first quarter increased 0.47% year-on-year
On April 24, Gelonghui Biotech (301156.SZ) released its first quarter report. Operating revenue was 97.906 million yuan, up 7.57% year on year, net profit of 9.58 million yuan, up 0.47% year on year, after deducting non-net profit of 8.979 million yuan, down 2.49% year on year, with basic earnings of 0.0856 yuan per share.
Meinong Biotech (301156.SZ): Products are currently mainly used in the fields of pigs, ruminants, poultry and aquatic products
On April 19, Ge Longhui (301156.SZ) held a performance briefing on April 19, 2024, to discuss “Does the company have any products for the pet market, and if so, what are the current plans? ”, the company replied that the company's products are currently mainly used in fields such as pigs, ruminants, poultry and aquatic products, and that the company currently receives pets such as couples and Forbes as representative customers. The company will promote corresponding business according to its own technological development and actual market demand.
Meinong Biotech (301156.SZ): Li Da plans to reduce its shares by no more than 1%
Gelonghui, April 18, 丨 Meinong Biotech (301156.SZ) announced that shareholder Li Da plans to reduce his holdings of the company's shares by no more than 1,107,281 shares (1% of the company's total share capital) through centralized bidding within 3 months after 15 trading days from the date of disclosure of this announcement.
No Data